Drugs / Sotoclax
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07550855 | Sep 2026 → Mar 2028 expected | follicular lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sotoclax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07550855 ↗ |
| Route | Oral | “Sotoclax oral administration” NCT07550855 ↗ |